Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

NEWS FEEDS

#TBT: Quality of Life, Innovation & Evidence Adoption

January 15, 2015

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous research, videos or commentaries in a relevant way. As the saying goes, “what’s old is new again” – and we hope you enjoy our wonky twist on #TBT.

January is International Quality of Life Month, and an often important component of many patients’ overall health and well-being is the use of pharmaceuticals to treat their conditions. Over the past decade, growing numbers of patients have benefited from new medicines and research, thanks to an accelerated pace in medical discovery and innovation. Although these findings can better patients’ lives, the health care system has not always kept pace when it comes to adapting these learnings and putting them into practice.

According to a 2001 Institute of Medicine report, application of new medical knowledge into practice takes an average of 17 years.

What accounts for this delay, and what factors are most influential in order for evidence to be more rapidly adopted? According to a National Pharmaceutical Council (NPC) study, “When Is Evidence Sufficient for Decision-Making? A Framework for Understanding the Pace of Evidence Adoption,” that was published in the July 2013 issue of the Journal of Comparative Effectiveness Research (and our Throwback Thursday pick), there are several reasons.

The study looked at three well-documented cases in which new information was disseminated to the public—statins, drug-eluting stents and bone marrow transplantation for breast cancer. The authors developed a framework to determine which factors were most influential in changing clinical practice. The framework includes the following considerations:  

  • Validity, reliability and maturity of the science: Is the current understanding of the particular condition and its treatment understood well enough so that new information can be taken into account?
  • Economic drivers that might influence adoption: Who is paying for the treatment? Is it being reimbursed? What marketing or detailing efforts were influential?
  • Rapid (or slow) incorporation into practice guidelines: How quickly—or slowly—were the results accepted by groups that develop guidelines?
  • Communication: Are the results being amplified by major media outlets, celebrities or social media?
  • Patients’ and providers’ ability to apply results to their needs: Can patients or providers apply published evidence to their decisions?

The overall goal of the framework is to encourage consideration of the critical factors that affect adoption and help to optimize the pace with which new treatments and new findings about treatments are brought into routine clinical practice. [Check out our archived webinar for a broader discussion of this study.]

In related research, RAND Associate Policy Researcher Dr. Justin Timbie examined the barriers that hinder the adoption of evidence into clinical practice. NPC spoke with Dr. Timbie in a 2012 interview in which he cited the misalignment of financial incentives, ambiguity of comparative effectiveness research (CER) results, cognitive biases, failure of CER design to address the needs of end-users, and limited use of decision support by patients and clinicians as key factors.

Commentary and Testimony Page

The Importance of Evidence, Value, Access and Innovation in 2016

Last year, in our 2015 Health Care Outlook published in Chain Drug Review, I highlighted the recent announcement by the U.S. Department of Health and...
Newsletter Volume

E.V.I.dently November 2015

MessageCan We Work Together to Ensure Patient Access to Treatments and Encourage Innovation?Has biopharmaceutical innovation brought value and made a...
Blog Post

Can We Work Together to Ensure Patient Access to Treatments and Encourage Innovation?

Is it possible for all health care stakeholders to work together to develop solutions for containing costs that ensure patient access to care and...
Blog Post

Pharmaceutical Innovation’s Role in the Panorama of Health System Improvement and Population Health

When he announced the launch of the White House Precision Medicine Initiative, President Obama said, “If we have the opportunity to prevent hurt and...
Press Release

Specialty Medications: Shifting the Focus From “How Much” We Spend to “How Well” We Spend

Washington, DC, June 9, 2014—As health care decision-makers grapple with how to ensure access to specialty medications, the University of Michigan...
Press Release

National Pharmaceutical Council Welcomes Amgen as Its Newest Member

Washington, D.C. (January 16, 2013)—The National Pharmaceutical Council (NPC) today welcomed biotechnology pioneer Amgen as its newest member. Joshua...
Press Release

National Pharmaceutical Council Expands Policy and Research Staff

WASHINGTON, DC (January 4, 2012) -- The National Pharmaceutical Council (NPC) announced the hiring of Daryl Pritchard, PhD, as the Director of...
Press Release

New NPC Report Provides Guidance on Evaluating Comparative Effectiveness Studies

WASHINGTON, D.C. (December 10, 2009) – A new report released today by the National Pharmaceutical Council (NPC) provides guidance in the evaluation...
Commentary and Testimony Page

The Importance of Evidence, Value, Access and Innovation in 2016

Last year, in our 2015 Health Care Outlook published in Chain Drug Review, I highlighted the recent announcement by the U.S. Department of Health and...
Commentary and Testimony Page

Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?

A growing chorus of voices is publicly sharing data on the effectiveness of treatment options, but one viewpoint has long been shut out of key areas...
Commentary and Testimony Page

Framework Helps ACOs Leverage Pharmaceuticals to Realize Quality, Cost Goals

Medications are more than an item on the balance sheet for health care providers. Pharmaceuticals offer a route to manage costs while achieving...
Commentary and Testimony Page

Comparative Effectiveness Research and the Changing Health Care Landscape

This content appeared in the January 2, 2012 print edition of Chain Drug Review. In the span of just one year, the health care landscape has...
YouTube Videos

Anthem's Malin: Communication Is Key to Success of Care Pathways

To make a clinical care pathway successful, “you have to work on many levels to engage providers,” says Dr. Jennifer Malin, medical director,...
YouTube Videos

Anthem's Malin: Having Patient-Level Data Can Improve Clinical Care Pathways

The success of a clinical care pathway is related to the breadth and quality of the information that is available to organizations developing...
YouTube Videos

Anthem's Dr. Malin on Care Pathways: Their Implementation and Evaluation

Dr. Jennifer Malin, medical director, oncology and care management, Anthem, Inc., explains that her organization uses care pathways to address the...
YouTube Videos

Anthem's Dr. Malin on Clinical Care Pathways and Innovation

Could clinical care pathways help innovation? Anthem Inc.'s Dr. Jennifer Malin, medical director, oncology and care management, says it’s a strong...
Blog Post

Can We Work Together to Ensure Patient Access to Treatments and Encourage Innovation?

Is it possible for all health care stakeholders to work together to develop solutions for containing costs that ensure patient access to care and...
Blog Post

Pharmaceutical Innovation’s Role in the Panorama of Health System Improvement and Population Health

When he announced the launch of the White House Precision Medicine Initiative, President Obama said, “If we have the opportunity to prevent hurt and...
Blog Post

At the HHS Pharmaceutical Forum, We Need to Consider All Health Care Costs

On November 20, stakeholders will come together for a day-long event—“HHS Pharmaceutical Forum: Innovation, Access, Affordability and Better Health”—...
Blog Post

Value Is in the Eye of the Beholder? NPC Takes Closer Look at ICER Framework

In recent months, a number of health organizations have developed “value assessment frameworks,” which are designed to inform coverage and treatment...

The Productivity Crisis in Pharmaceutical R&D

Although investment in pharmaceutical R&D has increased substantially in this time, the lack of...

Framing the Debate- Untangling the Potential Impact of Comparative Effectiveness Research on Innovation

Researchers integrated expert insight from a roundtable discussion into their own market research...
  •  
  • 1 of 5
  • >